NAUT: חוב להון עצמי Nautilus Biotechnology, Inc.

Nautilus Biotechnology (NAUT) brings together leading data science and bioengineering specialists, offering them complex challenges and generous stock options. Business success relies on the demand for proteomics in laboratories and the availability of funds for system implementation. The total debt-to-equity ratio is 0.23, which is clearly demonstrated by this chart on the GURU.Markets platform, serving as the primary valuation tool.

The total debt-to-equity ratio measures the proportion of borrowed funds within the financing structure, determining the business's degree of dependence on external creditors relative to its own resources. By analyzing the company's leverage history, an investor assesses the financial stability of Nautilus Biotechnology (NAUT), which is critical given the colossal expenditures required to develop proprietary proteomic platforms and create complex software.